ingitis, encephalitis, paralysis, acute respiratory illness, diarrhea, and sepsis [2] [3] [4] . However, since 2000, a number of countries, including England, Wales, Germany, Belgium, Spain, France, Israel, and Japan, reported aseptic meningitis outbreaks associated with this enterovirus [5] [6] [7] [8] [9] [10] [11] [12] .
In the past, nationwide aseptic meningitis outbreaks in the United States often have been associated with increased circulation of specific enterovirus serotypes, particularly echovirus types 11 (E11) and 30 (E30) [13] [14] [15] . During the most recent E11 and E30 outbreaks, genetically similar strains were isolated worldwide, demonstrating that enteroviruses may be rapidly transmitted on a global scale [14, 15] .
In 2001, E13 emerged as a prominent enterovirus in the United States, causing numerous aseptic meningitis outbreaks throughout the country [1] . This paper describes the epidemiologic and clinical characteristics of E13 activity in 2001 in the United States and demonstrates the genetic relationships among current E13
isolates from the United States and abroad. Enterovirus surveillance and aseptic meningitis outbreak data from Western Australia and New Zealand are presented for comparison. We also report the development of an E13-specific RT-PCR assay that may be used to rapidly differentiate E13 outbreak cases from sporadic cases due to other enterovirus serotypes.
METHODS AND MATERIALS
US enterovirus surveillance. Enterovirus surveillance data were compiled from several sources. CDC's National Enterovirus Surveillance System (NESS) collected enterovirus serotype data from participating state public health laboratories and 2 private diagnostic laboratories [13] . Some state laboratories also provided surveillance data to the pharmaceutical company Viropharma instead of, or in addition to, reporting to CDC through NESS. Although Viropharma shared their enterovirus data with CDC, the data were analyzed separately because of possible duplicate reporting by the states. Enterovirus data were also collected by the CDC Enterovirus Reference Laboratory during the course of diagnostic testing of specimens performed in support of outbreak investigations. Data on clinical and demographic characteristics obtained during outbreak investigations were provided by the corresponding state health departments. Historical data on E13 detections in the United States were obtained from NESS. Data on cases of E13-associated aseptic meningitis and encephalitis in New York were obtained through the New York State Encephalitis Initiative, an enhanced surveillance program for CNS infections in New York conducted by the Unexplained Encephalitis Study of the Emerging Infections Program, CDC.
Western Australia enterovirus surveillance. Year-round enterovirus surveillance is conducted for the Perth, Western Australia, metropolitan area at childcare centers. Weekly throat swab samples are obtained from healthy preschool-aged children attending the 10 participating childcare centers (total enrollment, ∼1500 children). Clinical samples from children admitted to a tertiary care, referral-based pediatric hospital in Perth are also tested.
New Zealand enterovirus surveillance. New Zealand enterovirus surveillance data were compiled by the Enterovirus Laboratory Network. This network serves the entire population and consists of 5 (1 public and 4 clinical) virology laboratories that provide routine diagnostic services to hospitals or general practice clinics. Untyped or untypeable enterovirus isolates are referred for identification to the Institute of Environmental Science and Research, Wellington, with possible further characterization performed at the World Health Organization regional reference laboratory (the Victorian Infectious Disease Reference Laboratory; Melbourne, Australia) or the CDC Enterovirus Reference Laboratory.
Identification of enteroviruses. Methods of enterovirus identification and typing varied among the laboratories. In general, virus was isolated from several types of specimens, including CSF, nasopharyngeal swab samples, rectal swab samples, and stool specimens. In some cases, panenterovirus RT-PCR was used for primary detection of enterovirus isolates recovered directly from specimens or from viral culture. Some laboratories screened isolates for the presence of enterovirus by indirect immunofluorescence, using monoclonal antibodies (Chemicon International) before performing more-specific testing. Typing of isolates was performed by an antibody neutralization test using intersecting pools of internationally standardized antisera [16] or by RT-PCR and partial sequencing of the VP1 gene [17] . The sequences reported here were deposited in GenBank (accession numbers AY331497-AY331563). Additional E13 partial VP1 sequences were retrieved from GenBank. Phylogenetic relationships among the E13 isolates were inferred from an alignment of the partial VP1 sequences using Clustal X, version 1.81 [18] .
E13-specific oligonucleotide primers for E13-specific PCR assays were designed to enable rapid identification of E13 in support of outbreak investigations, as described elsewhere for E30-and E11-specific primers [14, 15] . The deduced VP1 amino acid sequences of E13 reference strains were aligned to facilitate identification of E13-specific amino acid motifs for the synthesis of degenerate primers. Synthetic oligonucleotide primers 228S (5 -GA(dP)ACIATICARACIMGNTG-3 ; E13 VP1 amino acids 41-47; DTIQTRC) and 212A (5 -GCIG-CRTCICCRTGIGTRTC-3 ; E13 VP1 amino acids 75-81; DTHGDAA) were prepared, purified, and analyzed, as described elsewhere [19] . Degenerate sites in these oligonucleotide sequences are indicated by the following standard ambiguity codes:
C, G, or T; or G; or C; and N p A, R p A Mp A To reduce the number of unique primer I p deoxyinosine. species in primer 228S, we incorporated the pyrimidine base analog dP (dP-CE phosphoramidite; Glen Research) at a position that includes both T and C residues in the E13 reference strains [20] . In vitro RT-PCR amplification was performed using methods described elsewhere [21] .
RESULTS

US enterovirus surveillance.
In 2001, there were 1584 enterovirus isolates reported to the CDC, and 1072 reported to Viropharma. Overall, 36 states reported data to one or both surveillance systems (30 to the CDC and 18 to Viropharma). Of the 1584 isolates reported to the CDC, specific serotypes were identified for 1285 (81%) [22] . E13 accounted for 376 of 1584 isolates, constituting 24% of all isolates reported and 29% of isolates with an identified serotype and ranking second overall behind echovirus type 18 (E18; 31% of isolates for which a serotype was identified) for 2001. This represents a tremendous increase in E13 detections, compared with the numbers for previous years. Of the 30 states reporting enterovirus data to the CDC, 24 detected E13. These 24 states were distributed throughout the United States, with Illinois, Michigan, Tennessee, and Wisconsin reporting the most E13 detections [1] .
Of the 1072 isolates reported to Viropharma, a specific serotype was identified for 892 (83%). Two hundred twenty isolates were E13, which comprised 21% of all Viropharma isolates and 25% of isolates with an identified serotype. As with the data reported to the CDC, E13 ranked as the second most commonly reported serotype, behind E18 (32% of isolates for which a serotype was identified).
Aseptic meningitis outbreaks. In addition to its wide geographic distribution in 2001, E13 was associated, for the first time, with outbreaks of aseptic meningitis in the United States. Outbreaks were reported in the following 5 states: Louisiana, Mississippi, Montana, Tennessee, and Maryland. Nearly 75% of the cases in the Mississippi outbreak occurred in a county adjacent to the Louisiana parish (county) that reported the most aseptic meningitis cases for that state. All outbreaks were community-based and, with a few exceptions, involved patients with similar clinical and demographic characteristics (table 1) . The number of cases ranged from 23 in Montana to 303 in Tennessee [23] . Demographic and clinical characteristics of patients involved in these outbreaks are summarized in table 1. E13 was the most common serotype identified in each outbreak, followed by E18 (table 2) . CSF was the most common type of specimen tested.
Twenty-one cases of E13-associated CNS infection were reported to the New York State Encephalitis Initiative. These included 4 cases of encephalitis, 2 cases of meningoencephalitis, 13 cases of aseptic meningitis, and 2 cases with no specific diagnosis reported. The New York patients with E13 aseptic meningitis resembled the Maryland patients in age distribution and clinical symptoms (table 1). The available information on clinical and demographic characteristics was insufficient to describe the clinical features of E13-associated encephalitis.
Outbreaks of aseptic meningitis also occurred in 2001 in Perth and New Zealand. The epidemiologic characteristics of the Perth outbreak were similar to those of the outbreaks in the United States (table 1). E13 was isolated from 33 (39%) of 84 enterovirus-positive specimens (table 2) . Six of these E13 isolates came from throat swabs of healthy children attending sentinel childcare centers.
The New Zealand aseptic meningitis outbreak persisted from and their characteristics also resembled most of those of the US patients (table 1) . Of all 504 enterovirus isolates identified during the outbreak, 153 specimens (30%) from the 129 reported cases were positive for E13. E13 was most commonly isolated from stool (44% of isolates), followed by CSF (33%) and respiratory secretions (18%).
Virus isolation and identification. One hundred twentyone clinical specimens (114 CSF samples, 3 stool specimens, and 4 rectal swab samples) associated with aseptic meningitis outbreaks in 2001 in the United States were submitted to the CDC Enterovirus Reference Laboratory. Of the 114 CSF specimens, culture of 33 (29%) yielded enterovirus. Seven specimens (6%) were culture-negative, with positive results of enterovirus-specific RT-PCR. Results of culture and enterovirus-specific RT-PCR were negative for the remaining 81 specimens (71%). Twenty (61%) of the 33 isolates were identified as E13 by partial sequencing of the VP1 capsid gene; 6 were E18, 5 were coxsackievirus B2, and 2 were echovirus type 6. Culture of 2 of the 4 rectal swabs also yielded E13, and no virus was isolated from the 3 remaining rectal swabs and stool specimens.
In addition, 166 viral isolates were submitted from 20 states and 1 private laboratory for confirmation of antigenic typing results. Of these, 105 (63%) were identified as E13 by VP1 sequencing. The remaining isolates were identified as E18 (49 isolates); coxsackievirus B2 (3 isolates); coxsackievirus B4, echovirus type 3, echovirus type 16, and echovirus type 20 (2 isolates each); E30 (2 isolates); and human rhinovirus 1B (2 isolates from respiratory specimens).
Molecular epidemiology.
To elucidate the relationships among E13 isolates of diverse temporal and geographic origin, the partial VP1 sequences of the E13 outbreak isolates were compared with each other, with those of other E13 isolates in our collection, and with the E13 sequences available in the GenBank database. The outbreak isolates were 71%-74% identical to the E13 prototype strain (PHL53-Del Carmen), and !73% identical to the next nearest related enterovirus (EV) serotype, EV69 (prototype strain, MEX59-Toluca-1). All of the isolates were more closely related to PHL53-Del Carmen than to MEX59-Toluca-1 (data not shown).
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14 (54) 33 (59) 14 (61) 204 (67) 32 (28) 6 (46) 22 (67) 52 (40) у15 years 4 (15) 9 (16) 1 (4) 2 (1) 68 (60) 5 (39) 3 ( 9) 24 (19) Median ( to the Bangladesh isolates, and !86% identical to other E13 isolates from Samoa, the Dominican Republic, Chile, United States, Germany, and Paraguay ( figure 1B) . In many cases, temporally clustered isolates from a single US state (or from adjacent states) had identical or nearly identical partial VP1 sequences ( figure 1C) . Seven of 8 Louisiana isolates and 6 of 8 Mississippi isolates were identical to one another (cluster LA/MS/MD). These isolates were from specimens obtained from patients with aseptic meningitis who lived in adjoining counties or parishes across the border between the states. Similarly, 1 isolate from northern Mississippi had an identical sequence to those isolated in the adjacent region of Tennessee (cluster TN/MS/NY), and identical sequences were also observed in isolates from adjacent regions of Kentucky and Tennessee (cluster KY/TN/MD/IL). All isolates from a single state, however, did not necessarily cluster together. Isolates from all states for which 11 isolate was available formed at least 2 clusters, except for the 5 Montana isolates ( figure 1C) . Similarly, the 8 German isolates were distributed among 6 clusters. Conversely, closely related viruses were isolated in distant states (clusters LA/MS/MD, TN/MS/NY, MD/KY/FL/NY, and NC/ NY/FL/MS).
Development of E13-specific primers. A serotype-specific amino acid motif (DTIQTRC; E13 VP1 amino acids 41-47) was identified near the amino terminus of the VP1 sequence of the E13 prototype strain PHL53-Del Carmen. This amino acid motif was not found in the VP1 capsid sequence of any of the 63 other enterovirus serotypes. Examination of additional E13 VP1 sequences indicated that this motif was highly conserved among all members of the serotype. A deoxyinosinecontaining degenerate PCR primer (228S) was designed to recognize the site encoding this conserved amino acid motif. Another well-conserved, E13-specific amino acid motif was identified and targeted by the antisense primer (212A; DTHGDAA; E13 VP1 amino acids 75-81). Primer pair 228S-212A amplified the expected 122-bp product from all E13 isolates tested, including all US outbreak isolates and OMA98-10258, the most closely related isolate recovered before 2000 (64 of 64 tested were positive). An amino acid alignment of the remaining isolates showed that all isolates, except for the German isolates recovered from 1965-1979, also matched the target primer sites (data not shown). No PCR product was produced from any of the 63 other enterovirus serotypes (data not shown).
DISCUSSION
During 2001, E13 suddenly emerged as a predominant enterovirus serotype in the United States. It was associated with significant morbidity and with numerous outbreaks. The identification of 376 E13 isolates during 1 calendar year is unprecedented in the United States. The largest number of E13 isolates ever recorded in 1 year before 2001 was 8 in 1980 and 9 in 2000, comprising only 0.4% and 1.6% of all enterovirus isolates for those years, respectively. This pattern of sudden emergence of E13 is similar to observations noted in other countries. In England and Wales, E13 had been isolated only 19 times during the 10-year period before 2000 [6] , and it was rarely reported before 2000 in Germany, as well [7] . E13 had never been identified in New Zealand during the 25-year period before the 2001 outbreak. In Israel, E13 had been isolated only twice previously (in 1998 and 1999) [5] . Similarly, in Japan, E13 had been reported only once before 2001 (in 1980) [8] . A total of 49 isolations were reported in 2001 in Japan, and, in 2002, E13 became the most common cause of aseptic meningitis, accounting for 1527 reported cases (67%) nationwide [12] . There were 2099 E13 isolates (48% of all reported nonpolio enterovirus isolates) reported in Japan in 2002 [8] .
The frequency of isolation of a given enterovirus serotype tends to vary from year to year in temperate climates [25] . A number of serotypes have been observed to circulate in epidemic patterns, often being associated with outbreaks of clinical disease between periods of quiescence [14] . In addition, global circulation of enterovirus serotypes causing widespread clinical disease has been noted in the past, particularly with echovirus type 9, E30, and EV70 and EV71 [14, 26, 27] . Both of these characteristics describe the emergent pattern of E13, and preliminary surveillance data for 2002 indicate that it has returned to a quiescent state in the United States, with only 9 (0.2%) of a total of 489 reported enterovirus isolates having been identified as E13.
Like other enteroviruses, a wide range of clinical diseases (from subclinical infection to aseptic meningitis and encephalitis) was associated with E13. In the past, E13 has also been associated with other severe manifestations, such as bronchopneumonia, acute flaccid paralysis, and systemic neonatal enteroviral illness [2] [3] [4] . Although the most common clinical syndrome reported in association with the increased E13 activity was aseptic meningitis, other reported clinical manifestations included more severe conditions, such as encephalitis and meningoencephalitis. Consistent with the wide clinical range of enterovirus infections, several isolates came from asymptomatic children. However, more data are needed to fully define the spectrum of E13-associated disease.
Genetically similar E13 strains were associated with the aseptic meningitis outbreaks reported throughout the United States in 2001. Their close relationship to isolates from Australia, New Zealand, Japan, The Republic of Korea, Belgium, and Germany suggests that this same strain of E13 caused aseptic meningitis cases in those countries and, possibly, worldwide during 2000-2002. Given the temporal and phylogenetic relationships of these isolates, this E13 strain may have been imported into the United States, possibly by multiple introductions (i.e., у2 infected people introduced the virus independently of each other). The origin of the strain before its circulation in Europe and Oceania remains unknown. However, the closeness of the genetic relationship between the current E13 isolates and the earlier isolates from the Arabian peninsula (i.e., the Saudi Arabian 1989 isolate and two 1998 isolates from Oman) compared with that between all other isolates may suggest that the Middle East was a possible place of origin. This E13 strain was genetically quite different from strains isolated before 2000 and seems to have supplanted them in Europe and North America. At present, continued circulation of E13 strains similar to those earlier isolates is not evident, but the availability of worldwide virologic data is limited. On the other hand, a genetically distinct E13 lineage was observed in Bangladesh during 1999-2001, demonstrating the existence of at least 1 cocirculating lineage in addition to the outbreak strain in Europe, North America, and the western Pacific Rim. Other enteroviruses, such as E11 and E30, have been shown to undergo genetic variation over time, and this variability has been associated with changing circulation patterns and occurrence of enteroviral disease outbreaks [14, 15] .
The sudden emergence of E13 as a prominent enterovirus in the United States in 2001 demonstrates the potential of enteroviruses to circulate widely and unpredictably and cause considerable clinical disease, and it underscores the continued need for enterovirus surveillance. Currently, with no nonpolio enterovirus-associated diseases reportable in the United States, monitoring of geographic and temporal trends of enterovirus isolates can alert clinicians and public health officials to changes in enteroviral disease patterns. This information may assist in clinical intervention if anti-enterovirus drugs become available [28] . Continued awareness of enteroviral disease by clinicians, via enterovirus isolation and typing, and through reporting of enterovirus typing results to CDC by public health laboratories should continue to be encouraged.
